跳至主要内容
临床试验/KCT0002792
KCT0002792已完成未知

Evaluation of CAE on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

utraPharmTech0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
55(Year) 至 85(Year)(—)
性别
All

入选标准

  • Subject who have decreased CERAD-K(Consortium to Establish a Registry for Alzheimer’s Disease-Korean version) memory score(-1.0SD<=CERAD-K memory score) comparing to the same age and education group.

排除标准

  • 1. People who are being hospitalized or within 3 months after hospital discharge for any types of malignant tumors, severe cardiovascular diseases (stroke, hemorrhage, etc), and sever heart diseases (unstable angina, myocardial infarction, heart failure, arrhythmias requiring treatments).
  • 2. People who have major depressive disorders categorized by Diagnostic and Statistical Manual of Mental Disorders-IV
  • 3.People who have poor cognitive function and have Alzheimer’s disease, Parkinson’s disease, or stroke. (The diagnosis of Alzheimer’s disease is based on Diagnostic and Statistical Manual of Mental Disorders-IV)

研究者

发起方
utraPharmTech

相似试验